Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8412-8419

  Attig, Sebastian ^a   Hennenlotter, Jörg ^b   Pawelec, Graham ^b   Klein, Gerd ^b   Koch, Sven D ^c   Pircher, Hanspeter ^d   Feyerabend, Susan ^b   Wernet, Dorothee ^b   Stenzl, Arnulf ^b   Rammensee, Hans Georg ^a   Gouttefangeas, Cécile ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN;

ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MEMORY T LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUMOR CELLS, CULTURED;

EID: 70350537020     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0852     Document Type: Article

References (49)

1. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949 (Pubitemid 39273735)
2. + T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13:4345-4354
3. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162-179
4. Angevin E, Kremer F, Gaudin C, Hercend T, Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 1997;72:431-440 (Pubitemid 27325870)
5. Van den Hove LE, Van Gool SW, Van Poppel H, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997; 109:501-509 (Pubitemid 27402320)
6. Schleypen JS, Baur N, Kammerer R, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006;12:718-725 (Pubitemid 43259850)
7. Tatsumi T, Kierstead LS, Ranieri E, et al. Diseaseassociated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-628 (Pubitemid 35024440)
8. Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-4220
9. + T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 2005;115: 752-759
10. Dengjel J, Nastke MD, Gouttefangeas C, et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006;12: 4163-4170
11. Gouttefangeas C, Stenzl A, StevanovicS, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007;56:117-128
12. Frankenberger B, Noessner E, Schendel DJ. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007;17:330-343 (Pubitemid 47211966)
13. Seliger B, Atkins D, Bock M, et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen- processing down-regulation. Clin Cancer Res 2003; 9:1721-1727 (Pubitemid 36554596)
14. + regulatory T cells in patients treated with high-dose interleukin-2 for metastaticme lanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-1177
15. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-1753 (Pubitemid 47313079)
16. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-3048
17. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-6682
18. Whiteside TL. Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53:865-878
19. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22: 745-763 (Pubitemid 38680440)
20. + T lymphocytes. J Immunol 2007;178:4112-4119
21. Appay V, van Lier RA, Sallusto F, Roederer M. Pheno-type and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008;73:975-983
22. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258
23. Mulder WM, Koenen H, van de Muysenberg AJ, Bloemena E, Wagstaff J, Scheper RJ. Reduced expression of distinct T-cell CD molecules by collagenase/ DNase treatment. Cancer Immunol Immunother 1994;38:253-258 (Pubitemid 24108736)
24. Van Damme N, Baeten D, De Vos M, et al. Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers. J Immunol Methods 2000;236:27-35. (Pubitemid 30107906)
25. + donors. Eur J Immunol 2005;35: 2876-2885
26. + T cells. J Exp Med 1997;186:1407-1418
27. + T lymphocytes with cellular maturation. J Exp Med 2006;203:2865-2877
28. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-738 (Pubitemid 35177960)
29. Schwartzkopff S, Grundemann C, Schweier O, et al. Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans. J Immunol 2007;179:1022-1029
30. Nouwen EJ, Dauwe S, van dB I, De Broe ME. Stage-and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int 1993;44:147-158
31. 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 2007;204:559-570
32. Cozar JM, Canton J, Tallada M, et al. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 2005;54:858-866 (Pubitemid 40991328)
33. Wenzel J, Bekisch B, Uerlich M, Haller O, Bieber T, Tuting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 2005; 124:37-48. (Pubitemid 40944372)
34. Klatte T, Seligson DB, Leppert JT, et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008;179:61-66 (Pubitemid 350216740)
35. Finke JH, Rayman P, George R, et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-κB suppression. Clin Cancer Res 2001;7:940-6s. (Pubitemid 33600949)
36. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-3145 (Pubitemid 35155023)
37. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003;63:4481-4489
38. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178: 6730-6733 (Pubitemid 46847396)
39. + IL- 17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 2008;105:15505-15510
40. Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-2873 (Pubitemid 38500627)
41. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastaticmel anoma. Cancer Res 2003;63: 2535-2545
42. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666 (Pubitemid 41817714)
43. Yuan J, GnjaticS, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastaticm elanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008;105: 20410-20415
44. Imai N, Ikeda H, Tawara I, Shiku H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8(+) T cells. Eur J Immunol 2009;39:241-253
45. + T cells. Hum Immunol 2008;69:737-744
46. + T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-2081
47. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007;204: 239-243 (Pubitemid 46294539)
48. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964 (Pubitemid 44498003)
49. Kondo T, Nakazawa H, Ito F, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006;97:780-786 (Pubitemid 43983791)